TECVAYLI®▼ (teclistamab) monotherapy application submitted to the EMA for relapsed/refractory multiple myeloma after at least one prior therapy

TECVAYLI®▼ (teclistamab) monotherapy application submitted to the EMA for relapsed/refractory multiple myeloma after at least one prior therapy

Application supported by Phase 3 data reinforcing teclistamab regimens as a potential standard of care after at least one prior therapy1 Teclistamab...

Application supported by Phase 3 data reinforcing teclistamab regimens as a potential standard of care after at least one prior therapy1 Teclistamab monotherapy delivered superior progression-free s… [+15345 chars]

Related Posts

About FHMnews

What is FHMnews?

FHMnews is the result of a rebellion that transcended frustration. Look around you. As PK puts it, the people in this circle think one thing, say another, and do another. We shook up all three, confined within one circle, and decided to write as they think and speak. News, views, and everything beyond.

FHMnews is the country's first "new age" English news website. It's modern in its language, attitude, and news standards. It features selected news stories from the day, but with 360-degree coverage. It offers a complete report and analysis of each story, along with additional features like quizzes, polls, memes, and videos.

FHMnews Ltd.

E-43, Phase 8
Sahibzada Ajit Singh Nagar,
Punjab, 160071

Get In Touch With Us

© Copyright FHMnews
TECVAYLI®▼ (teclistamab) monotherapy application submitted to the EMA for relapsed/refractory multiple myeloma after at least one prior therapy - FHMnews